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Purpose
The purpose of this bulletin is to present Massachusetts-specific data related to maternal causes of
death and maternal mortality ratios from 1995 through 1998, summarize case review findings, and
suggest strategies for improving maternal outcomes.  This bulletin covers deaths from medical
causes associated with pregnancy (see page 2 for definitions).  Future bulletins will address other
causes of maternal deaths (e.g. drug overdose, homicide and other injuries), and additional
epidemiological mortality and morbidity analyses.
Background
A maternal death is a sentinel event.  During the last half of this century we have witnessed a
dramatic decrease in maternal mortality in Massachusetts.  Earlier work1 documents a decline from
50 per 100,000 live births in the early 1950s to 10 per 100,000 live births in 1985.  During those
same years, leading causes of maternal death shifted from infection, cardiac disease, pregnancy-
induced hypertension and hemorrhage to injury (i.e., suicides, homicides and motor vehicle
accidents) and pulmonary emboluS.2 According to the National Center for Health Statistics,
Massachusetts has the second lowest maternal mortality ratio in the U.S (3.3/100,000).3 These
unfortunate deaths teach important lessons to help prevent future mortality.  They also provide clues
for understanding maternal morbidity and improving women's health in general.
In 1997, the Commissioner of the Massachusetts Department of Public Health (MDPH) appointed a
Maternal Mortality and Morbidity Review Committee (MMMRC) to review maternal deaths, study the
incidence of pregnancy complications, and make recommendations to improve maternal outcomes
and prevent mortality.  The work of the committee is protected under M.G.L. c.111, section 24A and
24B, which assures the confidentiality of all records and proceedings.4 The committee consists of
obstetricians, certified nurse midwives, maternal fetal medicine specialists, a neonatologist and a
pathologist (see Appendix A).  This initiative follows the tradition of improving maternal health
through case review begun by the Committee on Maternal Welfare of the Massachusetts Medical
Society in 1941.  That effort was chaired by Dr. John F. Jewett from 1953 to 1985.5 Over time,
definitions of maternal death have evolved and case finding methods have improved, but the goal of
promoting maternal health has remained unchanged.
2Defining a Maternal Death
There is no standard definition of maternal mortality with respect to causes of death or timing of
death in relation to pregnancy.  Varying definitions used at state,6 na ional and international levels
make comparisons of mortality ratios across states and with national data quite difficult (see
Appendix B for definitions).  For example, the World Health Organization (WHO) and the National
Center for Health Statistics (NCHS) define maternal deaths as occurring either during pregnancy or
within 42 days after pregnancy termination.  Individual states, however, have adopted various time
intervals, from a minimum of 42 days to a maximum of 18 months postpartum.  The WHO recently
added a second category, called late maternal death, which includes deaths occurring between 42
and 365 days following the end of pregnancy.  Deaths caused by accidental or incidental causes or
from cancer are excluded under many definitions.  The MMMRC purposely chose a broad definition
of maternal mortality to permit the most thorough retrospective investigation possible.
Definition of Maternal Death Used in this Study
For the purposes of this investigation, the definition of maternal mortality recommended by the
Maternal Mortality Study Group, a national group jointly chaired by the Division of Reproductive
Health at the Centers for Diseases Control and Prevention (CDC) and the American College of
Obstetricians and Gynecologists (ACOG), was used.7 In accordance with that definition, the term
“pregnancy-associated" is used instead of “maternal” to reflect the inclusion of deaths occurring
during pregnancy.
Pregnancy-associated death: The death of a woman while pregnant or within one year of
termination of pregnancy, irrespective of cause.
Pregnancy-associated deaths are divided into three categories:
1. Pregnancy-related.  The death of a woman while pregnant or within one year of termination of
pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or
aggravated by her pregnancy or its management, but not from accidental or incidental causes .8
2. Pregnancy-associated-but-not-pregnancy-related.  The death of a woman while pregnant or
within one year of termination of pregnancy due to a cause unrelated to pregnancy.
3. Undetermined if pregnancy-related.  The death of a woman while pregnant or within one year
of termination of pregnancy, but the relationship of her death to pregnancy cannot be
determined.
The MMMRC further categorized deaths into those deaths that were caused by a medical condition,
and deaths caused by intentional or unintentional injury.
Pregnancy-Related Death:
If this woman had not been pregnant, would she have died?
3Mandatory Reporting of Maternal Deaths
Massachusetts hospitals are obligated to report to the MDPH's Division of Health Care Quality the
death of any woman during pregnancy or within 90 days of delivery or termination, regardless of the
cause of her death.  This regulation applies to deaths that occur in a hospital setting.
Submit reports by telephone or Fax:
Telephone: 617-753-8150
Fax: 617-753-8165
The Massachusetts Department of Public Health requires that “the death of a pregnant woman during
any stage of gestation, labor or delivery or the death of a woman within 90 days of delivery or
termination of pregnancy will be reported within 48 hours to the department by the hospital in which
the death occurs [105 CMR 130.628(C)].” 1989
Methods
Case Finding
Pregnancy-associated deaths occurring in Massachusetts from 1995 through 1998 were identified
through mandatory facility reporting to the MDPH Division of Health Care Quality, and manual and
automated reviews of death certificates.  In addition to these traditional case-finding methods, the
MMMRC employed an enhanced surveillance method linking birth certificates and fetal death
certificates to death certificates of reproductive-age women.  This approach has also been adopted
by other states.  These enhanced and improved surveillance methods in combination with the
ACOG/CDC definition identified more deaths than previously reported.
Case Review
All available hospital medical records related to each woman's pregnancy and death, as well as her
death certificate and certificates of infant birth or fetal death were obtained.  A primary and
secondary reviewer from the MMMRC analyzed all available documents and summarized each case
for the entire committee without identifying patients, clinicians, or institutions.  In addition, medical
specialists in oncology, neurology and infectious disease were asked to review specific cases.
During reviews, consensus was sought on answers to several questions:
· Was the death pregnancy-related?
· Was the death preventable?
· What public health and/or clinical strategies might prevent future deaths?
A “preventable death” is broadly defined as a death that may have been averted by one or more
changes in the health care system related to clinical care, facility infrastructure, public health
infrastructure and/or patient factors.
Reviews were limited to attainable records, and the following medical records and documents were
not reviewed by the committee: ambulatory care records not part of the hospital medical records; full
reports of autopsies conducted by state medical examiners; hospital records for births or fetal deaths
occurring outside of Massachusetts; and information about deaths or births occurring in non-hospital
settings.  These records may have provided additional insight.
4Mortality Ratios, Causes, and Timing of Death9
From 1995 through 1998, 88 women were identified (using the enhanced surveillance methods) who
met the definition of a pregnancy-associated death.  Three additional women were identified and
their cases reviewed, but their deaths occurred more than one year following pregnancy and were
therefore excluded from this analysis.10  Of the 88 deaths, 60 (68%) were caused by medical
conditions, i.e. were not the result of an injury or drug overdose.  The remaining 28 deaths were
caused by intentional or unintentional injuries and will be reviewed and reported on in the future.
Pregnancy-Associated Mortality Ratios11
Mortality (All Causes)
Year N Ratio
1995 21 25.4
1996 19 23.4
1997 25 30.8
1998 23 28.0
Total 88 26.9
Using the enhanced case finding
methodology, the pregnancy-associated
mortality ratio over the four-year period was
26.9 per 100,000 live births. Among the 60
deaths caused by medical conditions, the
pregnancy-related mortality ratio was
5.8/100,000, and the pregnancy associated
but not pregnancy-related mortality ratio
was1.6/100,000 (data not shown). These
ratios cannot be compared to other
publications due to differences in definitions
and case finding methodology.
Distribution of Maternal Deaths Caused by Medical Conditions
Among the deaths caused by medical
conditions, 19 (32%) were pregnancy-related,
38 (63%) were not related to pregnancy, and
in 3 (5%) cases it could not be determined
whether or not the deaths were related to
pregnancy based on available evidence.
Distribution of Pregnancy-Related Medical Causes of Death
The leading medical cause of pregnancy-
related death was infectious disease (26%),
followed by amniotic fluid embolism (21%)
and pregnancy-induced hypertension (16%).
Infectious diseases included septicemia,
sepsis and varicella.  Pregnancy-induced
hypertension included HELLP syndrome
(Hemolysis, Elevated Liver enzymes, and Low
Platelets) and eclampsia.  Other causes
included cerebrovascular, cardiovascular and
chronic conditions, and anesthetic
complications.
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5Pregnancy-associated but not pregnancy-related medical causes of
death
The leading cause of pregnancy-associated
but not pregnancy-related deaths was cancer
(33%) followed by infectious diseases (24%),
cardiovascular (16%) and chronic conditions
(16%).  Cancer deaths included melanoma,
lymphoma, leukemia, brain tumors and other
rare cancers.  Two women had pre-existing
diagnoses of cancer before they became
pregnant.  Infectious diseases included HIV,
meningitis, encephalitis, pneumonia, and
sepsis.  Chronic conditions included asthma,
diabetes, lupus and seizure disorders.  Other
causes included cerebrovascular and
iatrogenic conditions.
Timing of Medical Causes of Death
Thirty percent (n=18) of the deaths occurred either during pregnancy or within one week postpartum.
Almost all (94.8%) of the pregnancy-related deaths and one-third (34.2%) of the deaths not related to
pregnancy occurred within 42 days postpartum, a time coinciding with close contact with obstetrical
providers.
All Related Not Related Undetermined
Number of Days N % N % N % N %
<7 days 18 30.0 14 73.7 3 7.9 1 33.3
7-41 days 15 25.0 4 21.1 10 26.3 1 33.3
42-89 days 7 11.7 0 0.0 7 18.4 0 0.0
90-364 days 20 33.3 1 5.3 18 47.4 1 33.3
Total 60 100.0 19 100.0 38 100.0 3 100.0
Preventable Deaths
A "preventable death' is broadly defined as a death that may have been averted by one or more
changes in the health care system related to clinical care, facility infrastructure, public health
infrastructure and/or patient factors.  These determinations were made with the benefit of
retrospective review and current clinical practice guidelines at the time of the review rather than at
the time of the death.
Overall, 30% of the deaths (n=18) may have been preventable.  Among the pregnancy-related
deaths, 42% (n=8) may have been preventable, and among the deaths not related to pregnancy 26%
may have been preventable (n=10).  The preventability of 9 deaths (1 5%) could not be determined
from the information available at the time of review, and 33 deaths (55%) were probably not
preventable.
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6STRATEGIES TO SAFEGUARD MATERNAL HEALTH
Maternal death case reviews provided meaningful information about when, how and why women
died while pregnant or during the first year after the end of their pregnancy.  Although infrequent,
preventable deaths teach valuable lessons to avert future severe morbidity and deaths.  Using
composite case scenarios to provide a context for the reader, this section suggests strategies to
safeguard maternal health for clinicians, hospital and ambulatory care facilities, as well as the entire
public health community.  These recommendations are intended to stimulate discussion among all
those interested in improving maternal health and pregnancy outcomes and do not represent a
comprehensive approach.
Scenarios are composite vignettes drawn from two or more cases with key information changed to
protect the identities of patients and providers.
Strategies for Clinicians
Varicella
Scenario: A 30y/o woman with no known history of varicella was counseled to avoid exposure
during pregnancy. She had an uneventful labor and delivery. In the postpartum period she was
exposed and became symptomatic with varicella. Medical records did not indicate if she contacted
her provider or was offered VZIG. She became acutely ill, was hospitalized and eventually died of
disseminated varicella.
History of varicella.  All pregnant women should be asked about their history of childhood diseases
including varicella.  History of varicella is an excellent indication of immunity.
Counseling.  Pregnant and postpartum women without evidence of varicella infection by history or
seropositivity should be counseled to avoid contact with persons with chickenpox or shingles.  In
addition, these susceptible women should be instructed to call their obstetrical provider soon after
any varicella exposure during pregnancy and postpartum periods.  Susceptible pregnant women
should be counseled to receive their first dose of varicella vaccine in the postpartum period
Varicella Prevention:
· VZIG for pregnant and postpartum women.  Susceptible pregnant women who are exposed
to varicella infection should be given varicella zoster immune globulin (VZIG) within 96 hours of
exposure.  Given the short time frame for administration of VZIG after exposure, verifying
seronegativity may not be possible.  VZIG may be given at any time during pregnancy and is free
to all MA residents (see Appendix C).  Postpartum women have the option of receiving VZIG or
varicella vaccine for prophylaxis.
· VZIG for infants.  Infants whose mothers had an onset of varicella symptoms within five days
before delivery and up to 48 hours after delivery, should also receive VZIG.
· Varicella vaccine.  Susceptible non-pregnant women of childbearing age should be offered
varicella vaccine (two doses administered four weeks apart).  Pregnancy should be avoided for
one month following each dose of vaccine.  In lieu of VZIG, varicella vaccine can also be given
to susceptible non-pregnant women, including postpartum women, within 72 hours after
exposure to varicella infection.
· Report varicella vaccine use in pregnancy.  If varicella vaccine is inadvertently given within
one month of pregnancy, the likelihood of untoward effect is considered to be extremely small.
All such cases should be reported to the VARIVAX Pregnancy Registry (see Appendix C).
7Influenza
Scenario: A 35 ylo woman, G2P1, delivered an infant without complications. Several days after her
delivery she developed a flu-like syndrome. Approximately one week later the patient developed adult
respiratory distress syndrome secondary to multilobar pneumoccocal pneumonia. Her condition
worsened rapidly and she never recovered. Final cause of death was pneumococcal pneumonia
superimposed on viral infection. Influenza A infection was confirmed.
Influenza vaccine.  Recent evaluation of published data suggests that an average of 1-2
hospitalizations per 1,000 pregnant women could be prevented in each average influenza season by
immunizing pregnant women." The Advisory Committee on Immunization Practices (ACIP) of the
Centers for Disease Control and Prevention (CDC) recommends routine influenza immunization of
women who will be in the second or third trimester of pregnancy during influenza season.  Pregnant
women with medical conditions that increase their risk of complications from influenza should be
vaccinated regardless of stage of pregnancy.  Immunization during pregnancy with the inactivated
vaccine is considered safe by many experts, however some providers prefer not to administer the
vaccine during the first trimester to avoid association with spontaneous abortion that might occur
coincidentally (see Appendix C).
Pneumococcal vaccine.  Current American College of Obstetricians and Gynecologists and
ACIP/CDC recommendations state that women with high risk conditions for pneumococcal disease
(e.g., lung disease, asthma, asplenia) be vaccinated, preferably before pregnancy.  If an
unvaccinated, high-risk woman becomes pregnant, some authorities in the field advise deferring
immunization until after the first trimester (see Appendix C).
HIV Infection
Scenario: A 25 ylo pregnant woman with HIV infection presented with dyspnea and a CD4 count of
14 in her last trimester. She was diagnosed with Pneumocystis carinii pneumonia and started on
treatment. She went into labor and delivered a viable preterm infant. Her respiratory condition never
improved and she eventually died of complications. Although this patient had been receiving HIV care
of unknown frequency from an infectious disease specialist, her obstetrical provider was unaware of
the HIV status or any HIV-related treatment she was receiving.
Counseling and testing.  After counseling about HIV infection, providers should recommend and
offer HIV antibody testing to all pregnant women and all women considering pregnancy.
Treatment.  The medical treatment goal for HIV-infected women, pregnant or not, is to maintain
optimal health of the woman.  All HIV-infected pregnant women who are in care should be offered
antiretroviral therapy.  Treatment decisions should consider both the pregnant woman's well being
and the prevention of vertical transmission to her infant.
Coordination of care between obstetrical and HIV provider.  HIV treatment is more successful
but far more complex given the variety of pharmacologic regimes available.  It is important that a
provider with experience in the management of HIV be directly involved in the woman's care.  This
means that an HIV-infected woman should be receiving care from both an obstetrical provider and
an HIV specialist during pregnancy and the postpartum period.  Care should be provided in a
collaborative manner to maximize the health of the mother and minimize risks to the fetus and baby.
Case Management.  Patients with HIV infection who may have difficulty adhering to a treatment
regimen or have other complex issues should be referred for case management services.
8Septicemia
Scenario: A 22 y/o G2P1 in her second trimester developed a fever over 1030F without focal signs or
symptoms. Cultures were taken and the patient was sent home. Her condition worsened and she
presented at the emergency department where fetal demise was diagnosed. She deteriorated rapidly
with onset of septic shock. Her underlying cause of death was determined to be beta-hemolytic
Group A streptococcal sepsis.
Treatment.  A woman in the peripartum who shows signs of septicemia should be treated with
broad-spectrum antibiotics and screened for disseminated intravascular coagulopathy (DIC).
Empiric antibiotic treatment should begin before the final determination of a pathogen.  Group A
betahemolytic Streptococcus pyogenes is a very rare cause of puerperal infection in the present era,
however it can still cause maternal death.  Strep. pyogenes can produce an exotoxin that can cause
a toxic shock-like syndrome and/or DIC.  This pathogen can also present as bacteria with or without
symptoms and as an upper respiratory tract infection.
Septic Shock. In cases of fetal demise, prompt diagnosis and treatment of septic shock and DIC are
required.
Pregnancy Induced Hypertension (PIH)
Scenario: A 36 ylo G1PO was admitted at 34 weeks in early labor with a diagnosis of PIH
(B/P144/94, +4 protenuria and +4 reflexes). She was induced and delivered without complications.
After delivery the patient’s blood pressure continued to be elevated and she complained of epigastric
pain and nausea. Her lab values were consistent with HELLP. Treatment included magnesium sulfate
and monitoring on a regular postpartum floor. Approximately 40 hours after delivery she had multiple
grand mal seizures. Her condition deteriorated and she never recovered. Postmortem findings were
consistent with eclampsia with DIC.
Management.  HELLP, including immediate postpartum cases, should be managed aggressively.  If
the patient's condition worsens she should be transferred to a unit with a high staff to patient ratio.
The ACOG Technical Bulletin of Hypertension in Pregnancy reviews methods and techniques of
practice for obstetrical providers (see Appendix C).
Chronic Conditions
Scenario: A 35 y/o G1PO had a documented history of cardiac arrhythmia which was controlled by
medication. When she became pregnant, she discontinued her medication without consulting a
cardiologist. Two months postpartum the patient had palpitations, collapsed suddenly and could not
be resuscitated by the EMTs.
Co-management of chronic illness.  If a patient gives a history of a chronic or life threatening
illness, confirm that she is receiving the appropriate primary and consultant care during pregnancy
and postpartum.
Non-adherence to medication regimen.  Obstetrical providers should monitor patients' adherence
to chronic medication regimes.  Appropriate medical consultation should be obtained if a patient has
independently discontinued taking a medication for a potentially life threatening condition.
9Eating Disorders
Scenario: A 34 y/o G4P2 with a past  history of bulimia had a pregnancy and birth without
complications. Five weeks postpartum she collapsed and was admitted in a coma. She never
regained consciousness. Apparently she had been purging daily to reduce her weight.
Screening and Referral.  Women with histories of eating disorders are at risk for an exacerbation of
this problem during the prenatal and postpartum periods.  All pregnant and postpartum women
should be screened for eating disorders and referred as appropriate.
Strategies for Hospital and Ambulatory Care Facilities
Anesthesia and Analgesics
Scenario: A 35 y/o G4P2 had a difficult labor and delivered by cesarean section. She received
various analgesics through epidural, IV and IM routes during labor and delivery, in the recovery room,
and on the postpartum floor. Her care was managed by several providers and through different shifts
of nursing staff. No system was in place to track the cumulative amount of narcotics administered.
Monitoring.  The administration of analgesics should be monitored closely for cumulative amount,
particularly for women whose care is managed by multiple providers (e.g. anesthesia, obstetrics).
Care of Critically Ill Patients
Scenario: A 33 y/o G3P2 with a postpartum wound infection, developed shortness of breath, chest pain
and respiratory arrest. She was resuscitated but needed mechanical ventilation. The patient was
transferred to an intensive care unit, but needed isolation because of her wound infection. When her
respirator malfunctioned, no staff were available to assist her.
Policies and Procedures
· Existing policies requiring minimum staffing levels for critically ill patients and protocols for
monitoring life-support equipment should be followed.
· Emergency equipment and procedures should be reviewed on a regular, established schedule.
· Guidelines should be established for oversight of the care of critically ill obstetrical patients by
senior medical staff.
· If the need for more intensive obstetrical and neonatal care is anticipated, the patient should be
transferred to a hospital with an appropriate level of care.
Documentation
Scenario: A 43 y/o Spanish-speaking G8PO with a history of infertility had a cerclage placed early in
pregnancy. At 27 weeks she began bleeding and had signs of infection. She refused removal of the
cerclage to preserve her pregnancy and subsequently developed septicemia and died. Medical
records did not indicate that an interpreter was provided or that she understood the risks she was
taking in refusing treatment.
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When applicable the following information should be recorded in each patient's record:
· Written informed patient consent or non-consent for services or treatment, particularly when
patient decisions may negatively effect patient's life and outcome of pregnancy.
· Offer and receipt of social services.
· Explicit chronology during emergencies or during the care of critically ill patients.
· Use of translation and interpreter services.
· Prenatal care record in obstetrical inpatient record after the third trimester.
Strategies for the Public Health Community
Access
Scenario: A 38 y/o G3P2 non-English speaking Hispanic woman was enrolled in Healthy Start
during her pregnancy. Several months postpartum she developed nausea and vomiting and
eventually became non-responsive. When she arrived at the emergency department she was
comatose with severe diabetic ketoacidosis and never recovered. Staff had difficulty communicating
with family members and could not determine if she had seen a primary care provider since she had
given birth
Translation Services
· Hospital and other health care facilities should provide medical interpreter services for non-
English speaking patients.
· According to MDPH regulation 105 CMR:130 615(c), health education materials and activities
shall be available in the languages of any non-English speaking group which comprises at
least 10% of the population served by the maternal-newborn services.
Transition from Obstetrical to Primary Care:
· All patients, including those patients enrolled in Healthy Start or the uncompensated care pool,
should be referred to a primary care provider after obstetrical care is completed.
· Outreach services for the Healthy Start program should expand to the postpartum period to
assist women in accessing ongoing primary care.
Preconception care
· Public health professionals and clinicians working with women of child-bearing age should
offer information about family planning services, early signs of pregnancy, warning signs of
miscarriage and associated sepsis, and the importance of seeking early prenatal care.
· Public health professionals and clinicians working with women of child-bearing age with
chronic or life threatening conditions should provide pre-conception counseling about the
impact of pregnancy on her health, the impact of her condition on pregnancy, and options
available for family planning.
Skin Cancer
Scenario: A 25y/o G2P1 delivered a healthy infant without complications. Two months postpartum
she was diagnosed with metastatic malignant melanoma. She had neglected to tell her prenatal
provider that she had had a bleeding lesion on her scalp for at least 6 months.
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Periodic Screening.  All women should be encouraged to have a complete skin exam, including the
scalp, by a specially trained health care provider, beginning as early as age 20.  In families with a
history of melanoma, screening should begin between ages 12 and 14.  The American Cancer
Society recommends a cancer-related checkup, including skin examination, every three years for
people between 20 and 40 years of age, and every year for anyone age 40 and older.
Cardiovascular Disease
Scenario: After successfully quitting during her pregnancy, a 42 y/o G3P3 resumed smoking a pack
of cigarettes per day after delivery. She had been complaining of “bad indigestion” for a couple of
days when she suffered a fatal heart attack at her workplace.
Screening and Education
· Screen all patients with a history of smoking for relapse or continued smoking postpartum.
Counsel and refer for cessation as needed.
· Health education programs in schools and anticipatory guidance in all patient age groups by
primary care clinicians should include prevention strategies for cancer and cardiovascular
disease.
Conclusions
Maternal death, while rare, is a critical health indicator for women giving birth in the Commonwealth.
Improved and expanded case-finding methods used in this study facilitated the identification of more
deaths than previously noted and demonstrate the importance of expert case review in conjunction
with an active maternal mortality surveillance system. The review of medical causes of maternal
death suggests that some of these deaths may have been prevented.  Lessons learned from these
deaths can enhance the development of a comprehensive strategy to improve women's health at
clinical, institutional and community levels.
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Appendix B: Other Definitions of Maternal Death
1. World Health Organization (WHO), International Classification of Diseases, Ninth Revision
(ICD-9) and Tenth Revision (ICD-10):15
Maternal death:
The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of
the duration and the site of the pregnancy, from any cause related to or aggravated by the pregnancy
or its management but not from accidental or incidental causes.
Two additional definitions have been added to ICD-10:
Late maternal death:
The death of a woman from direct or indirect obstetric causes more than 42 days but less than 1 year
after the termination of pregnancy.
Pregnancy-related death:
The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of
the cause of the death.
2. National Center for Health Statistics (NCHS):
Deaths that occur during pregnancy or within 42 days after pregnancy termination, regardless of
pregnancy duration and site, from any cause related to or aggravated by the pregnancy, but not from
accidental or incidental causes.
3. Other state maternal mortality review efforts:
A number of other states have conducted maternal mortality reviews.  Definitions of maternal death
vary by time interval from the end of pregnancy until death, and causes of death.  All state
definitions include deaths that occur during pregnancy.  However, the interval of time between the
end of pregnancy and death varies from a minimum of 42 days to a maximum of 18 months.  Some
states, similar to Massachusetts, consider all causes of maternal deaths occurring within a specified
time period, while other states restrict their definitions to pregnancy-related deaths only.  Deaths
from injuries and cancer often are omitted from review because they are considered to be non-
pregnancy-related.  Variation in definitions, case inclusion and exclusion criteria, and case finding
methods, results in mortality ratios that are not comparable across states.
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Appendix C: List of Resources
Infectious Disease:
Telephone numbers
· Varicella zoster immune globulin (VZIG): For information about obtaining free VZIG call 617-522-
3700
· VARIVAX Pregnancy Registry (1-800-986-8999).  All cases of varicella vaccine given while pregnant
or within four weeks before pregnancy should be reported to the registry.
· HIV testing number 1-800-750-2016 (consumer)
· HIV information and counseling number 1-800-235-2331 (consumer)
Recommendations
· U.S. Public Health Service Task Force.  "Recommendations for the Use of Antiretroviral Drugs in
Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1
Transmission in the United States".  MMWR 1998, Jan 30; 47(RR-2): 1-30.  Guidelines updated in
2000 are available in PDF and HTML format at http://www.hivatis.org/trtgdlns.html#Perinatal
· General recommendations on immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP).  MMWR 1994; 43 (RR-1).
· Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices
(ACIP).  MMWR 1996; 45 (RR-11).
· Prevention of varicella updated: recommendations of the Advisory Committee on Immunization
Practices (ACIP).  MMWR 1999; 48(RR-06).
· Prevention and control of influenza: recommendations of the Advisory Committee on Immunization
Practices (ACIP).  MMWR 1999; 48(RR-04).
All immunization recommendations are available at http://www2.cdc.gov/mmwr/
Management of PIH:
ACOG Technical Bulletin of Hypertension in Pregnancy, Number 219, January 1996
Translation and Interpreter Services:
A listing of qualified vendors of translation and interpreter services that contract with various state
entities may be found on the Commonwealth of Massachusetts website: http://www.comm-PASS.com
Search the site using the following criteria:
Document Type: closed
Purchasing Entity: Operational Services Division
Product Category: Professional Services
Keyword: translation
Select Foreign Language Written Translation & Oral Interpretation Services, Reference No:
ST8J51 1; Contractor Contact Listing with Language, Rate and Zone Information.
